Document Detail

Effects of 17beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth factor-beta1 and insulin-like growth factor-1 in primary human osteoblast cultures.
MedLine Citation:
PMID:  15762036     Owner:  NLM     Status:  MEDLINE    
We investigated the effects of 17betaestradiol and two selective estrogen receptor modulators, tamoxifen and raloxifene, on the expression and release of constitutive and interleukin-1-stimulated interleukin (IL)-6, transforming growth factor-beta1 (TGF-beta1) and insulin-like growth factor-1 by osteoblasts in primary culture from trabecular bone of healthy post-menopausal women. After 24 h incubation with 10(-8) M concentration of these compounds, there was no decrease in: a) the constitutive or IL-1beta-induced levels of IL-6 protein released to culture medium; b) the constitutive IL-6 mRNA expression after incubation of osteoblasts with 10(-8) M 17betaestradiol or 10(-8) M tamoxifen for 1, 3, 6, 24 or 30 h. Although a decrease after 30 h of treatment with 10(-8) M, raloxifene was found in mRNA IL-6 expression, and this fact was not reflected by a decrease in the release of IL-6 protein to the culture medium after 48 h of incubation with 10(-8) M or 10(-7) M raloxifene. Tumoral growth factorTGF-betal expression was not influenced by incubation with these compounds. Gene expression of IGF-I increased following 24 or 30 h incubation with 10(-8) M 17beta-estradiol and 30 h incubation with raloxifene. Tamoxifen did not affect IGF-I expression. In conclusion, the effects of estradiol or tamoxifen on bone metabolism do not appear to be mediated through the regulation of osteoblast IL-6 release or synthesis, but raloxifene produces a decrease in mRNA IL-6 expression. The actions of estradiol, tamoxifen and raloxifene do not appear to be mediated by tumoral growth factor TGF-beta1. On the other hand, an increase in IGF-I synthesis induced by raloxifene and estradiol could mediate, in part, the effects of these compounds on bone.
C Méndez-Dávila; C García-Moreno; C Turbì; C de la Piedra
Related Documents :
9475116 - Neuronal reactivation of herpes simplex virus may involve interleukin-6.
7565736 - Pu.1 (spi-1) and c/ebp alpha regulate expression of the granulocyte-macrophage colony-s...
15735656 - Stimulus-dependent glucocorticoid-resistance of gm-csf production in human cultured air...
9846836 - B7-1 (cd80), b7-2 (cd86), interleukin-12 and transforming growth factor-beta mrna expre...
22410126 - Anger expression in swiss adolescents: establishing measurement invariance across gende...
11342116 - Molecular cloning of palbh, a mammalian homologue of the aspergillus atypical calpain p...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of endocrinological investigation     Volume:  27     ISSN:  0391-4097     ISO Abbreviation:  J. Endocrinol. Invest.     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2005-03-14     Completed Date:  2005-06-07     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7806594     Medline TA:  J Endocrinol Invest     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  904-12     Citation Subset:  IM    
Bone Pathophysiology Laboratory, Fundación Jiménez Diaz, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Hormonal / pharmacology*
Cell Culture Techniques
Estradiol / pharmacology*
Estrogen Antagonists / pharmacology*
Insulin-Like Growth Factor I / biosynthesis*
Interleukin-6 / biosynthesis*
Middle Aged
Osteoblasts / physiology*
Osteoporosis / physiopathology
RNA, Messenger / biosynthesis
Raloxifene / pharmacology*
Tamoxifen / pharmacology*
Transforming Growth Factor beta / biosynthesis*
Transforming Growth Factor beta1
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Estrogen Antagonists; 0/Interleukin-6; 0/RNA, Messenger; 0/TGFB1 protein, human; 0/Transforming Growth Factor beta; 0/Transforming Growth Factor beta1; 10540-29-1/Tamoxifen; 50-28-2/Estradiol; 67763-96-6/Insulin-Like Growth Factor I; 84449-90-1/Raloxifene

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The effect of L-thyroxine replacement therapy on lipid based cardiovascular risk in subclinical hypo...
Next Document:  Younger age at diagnosis of type 1 diabetes mellitus in children of immigrated families born in Ital...